199 related articles for article (PubMed ID: 32852708)
21. FGFR1 is an adverse outcome indicator for luminal A breast cancers.
Shi YJ; Tsang JY; Ni YB; Chan SK; Chan KF; Tse GM
Oncotarget; 2016 Jan; 7(4):5063-73. PubMed ID: 26673008
[TBL] [Abstract][Full Text] [Related]
22. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.
Jang M; Kim E; Choi Y; Lee H; Kim Y; Kim J; Kang E; Kim SW; Kim I; Park S
Breast Cancer Res; 2012 Aug; 14(4):R115. PubMed ID: 22863309
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
Saridogan T; Akcakanat A; Zhao M; Evans KW; Yuca E; Scott S; Kirby BP; Zheng X; Ha MJ; Chen H; Ng PKS; DiPeri TP; Mills GB; Rodon Ahnert J; Damodaran S; Meric-Bernstam F
Sci Rep; 2023 Nov; 13(1):20223. PubMed ID: 37980453
[TBL] [Abstract][Full Text] [Related]
24. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
25. Detection of CCND1 , C-MYC , and FGFR1 amplification using modified SYBR Green qPCR and FISH in breast cancer.
Azarnezhad A; Tabrizi M; Javan F; Mehdipour P
Turk J Med Sci; 2018 Aug; 48(4):759-767. PubMed ID: 30119151
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.
Clauditz TS; Böttcher A; Hanken H; Borgmann K; Sauter G; Wilczak W; Grob T; Münscher A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):53-61. PubMed ID: 29022097
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.
Starska K; Forma E; Lewy-Trenda I; Stasikowska-Kanicka O; Skóra M; Bryś M
Cell Oncol (Dordr); 2018 Jun; 41(3):253-268. PubMed ID: 29299828
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
Kim HS; Lee SE; Bae YS; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Jung DH; Shin SK; Lee SK; Lee YC; Kim HR; Moon YW; Kim JH; Shim YM; Jewell SS; Kim H; Choi YL; Cho BC
Oncotarget; 2015 Feb; 6(4):2562-72. PubMed ID: 25537505
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implications of
Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
[TBL] [Abstract][Full Text] [Related]
30. Dlg-1 Interacts With and Regulates the Activities of Fibroblast Growth Factor Receptors and EphA2 in the Mouse Lens.
Lee S; Shatadal S; Griep AE
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):707-18. PubMed ID: 26906157
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
[TBL] [Abstract][Full Text] [Related]
32. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
33. Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.
Passos-Bueno MR; Sertié AL; Richieri-Costa A; Alonso LG; Zatz M; Alonso N; Brunoni D; Ribeiro SF
Am J Med Genet; 1998 Jul; 78(3):237-41. PubMed ID: 9677057
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor receptor 1 protein (FGFR1) as potential prognostic and predictive marker in patients with luminal B breast cancers overexpressing human epidermal receptor 2 protein (HER2).
Amina B; Lynda AK; Sonia S; Adel B; Jelloul BH; Miloud M; Tewfik S
Indian J Pathol Microbiol; 2021; 64(2):254-260. PubMed ID: 33851617
[TBL] [Abstract][Full Text] [Related]
35. Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
Thomas A; Lee JH; Abdullaev Z; Park KS; Pineda M; Saidkhodjaeva L; Miettinen M; Wang Y; Pack SD; Giaccone G
J Thorac Oncol; 2014 Apr; 9(4):567-71. PubMed ID: 24736083
[TBL] [Abstract][Full Text] [Related]
36. FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis.
Fromme JE; Schmitz K; Wachter A; Grzelinski M; Zielinski D; Koppel C; Conradi LC; Homayounfar K; Hugo T; Hugo S; Lukat L; Rüschoff J; Ströbel P; Ghadimi M; Beißbarth T; Reuter-Jessen K; Bleckmann A; Schildhaus HU
Oncotarget; 2018 Aug; 9(63):32204-32218. PubMed ID: 30181810
[TBL] [Abstract][Full Text] [Related]
37. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Turner N; Pearson A; Sharpe R; Lambros M; Geyer F; Lopez-Garcia MA; Natrajan R; Marchio C; Iorns E; Mackay A; Gillett C; Grigoriadis A; Tutt A; Reis-Filho JS; Ashworth A
Cancer Res; 2010 Mar; 70(5):2085-94. PubMed ID: 20179196
[TBL] [Abstract][Full Text] [Related]
38. CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors.
Heiskanen M; Kononen J; Bärlund M; Torhorst J; Sauter G; Kallioniemi A; Kallioniemi O
Anal Cell Pathol; 2001; 22(4):229-34. PubMed ID: 11564899
[TBL] [Abstract][Full Text] [Related]
39. Association Between Fibroblast Growth Factor Receptor 1 Gene Amplification and Human Papillomavirus Prevalence in Tonsillar Squamous Cell Carcinoma With Clinicopathologic Analysis.
Park S; Lee M; Cho KJ; Kim SB; Roh JL; Choi SH; Nam SY; Kim SY; Song JS
J Histochem Cytochem; 2018 Jul; 66(7):511-522. PubMed ID: 29553868
[TBL] [Abstract][Full Text] [Related]
40. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
